Blogs

The pro-life v. pro-choice debate continued on the House floor yesterday as party representatives grappled with sustaining women’s reproductive rights in a surfacing abortion bill.  On Tuesday, the House of Representatives approved a bill banning a woman’s right to pursue an abortion after 22 weeks of pregnancy, subtracting two weeks off the current cut-off of abortions at 24 weeks in utero.  The majority-Republican party passed this bill shaving off the extra two weeks based off the medically disputed theory that a fetus is capable of feeling pain 20 weeks after conception (which is equivalent to 22 weeks of pregnancy).  Democrats in the House and the White House fought against the bill, saying the legislation is an “assault on a woman’s right to choose” and is an attempt to undermine the precedent set in the 1973 Roe v. Wade trial.
The argument quickly split down party lines (only six party members from each side voting against their party) and escalated into a debate on women’s reproductive rights.  In this heated bipartisan debate, representatives from both sides evoked emotional appeals.  Though different in message, consistent across both lines is the lack of the female voice.  While the House attempted to integrate more women in this debate, only 19 of the 222 Republican House members who voted for this bill are women.  In total, the House of Representatives only has 78 women, accounting for a meager 18% voice in the House.  Furthermore, there are no Republican women on the Judiciary Committee panel that has jurisdiction over this particular legislation.
While this bill certainly made headlines, the threat of it obtaining further approval is low.  Sources agree that the bill will not find support in the Democrat-controlled Senate, and President Obama has also already voiced his opposition.  Although no abortion laws are changing today, it is important to keep abreast on the dialogue surrounding this controversial and emotional topic.  Most importantly, government representatives must do a better job of allowing women’s voices and opinions to be heard.  Female reproductive rights issues have been considered taboo for too long, and an open dialogue in the government may help bridge the gap between women and policy.
Sources: ABC News, USA Today, and The New York Times.
 

Geneticists, researchers, and patients joined in celebration over last week’s unanimous Supreme Court ruling involving the BRCA1 and BRCA2 genes, colloquially referred to as the “breast cancer genes.”  The Supreme Court ruled that Myriad Genetics could not patent the BRCA1 and BRCA2 sequence of genes, because patents cannot be placed on that which is created organically in nature.  This decision opens the door for researchers outside of Myriad Genetics to study these genes, providing more opportunities to discover early signs of breast cancer susceptibility.  Karuna Jaggar, Breast Cancer Action’s Executive Director reported that this ruling was, “a tremendous victory for women with a known or suspected inherited risk of breast cancer. Today, the Court righted a wrong and has put patients’ health before corporate profits.”
Prior to this ruling, bio-tech conglomerate, Myriad Genetics, held patents on the BRCA1 and BRCA2 genes, monopolizing the research that can be done on these genes, which are strong indicators of susceptibility to breast cancer. Myriad had used their patents to come up with its BRACAnalysis test, which searches for specific mutations in these cancer predisposition genes.  Women who show these mutations have a three to seven times greater risk of developing breast cancer.  Myriad’s previously established patents on these genes gave them exclusive rights to use this genetic test on these genes.  Now that the BRCA1 and BRCA2 genes are open to outside researchers, scientists can use these genes to determine increased risks of patients who may develop breast cancer, ovarian cancer, and other cancers that these genes may help indicate.
Angelina Jolie recently made headlines for deciding to voluntarily undergo a double mastectomy after learning of her own BRCA genes’ mutations.  Jolie had paid a high price for this test, since Myriad had a monopoly on the market, driving up the cost.  So what does this mean for the average, non­-Angelina Jolie woman? Well, now this test will be widely available for more women at a more affordable price (we don’t all have as deep of pockets as Jolie).  This ruling will not only open the door for more opportunities for preventative screenings for breast cancer, but it will set a precedent for the scientific community to collaborate on research towards the common good.
For more information on this court ruling, please refer to this posts’s sources found here and here.
 

 
Policy changes are necessary to decrease the death rate of pregnant women in developing countries.  Research, according to Dr. Stacie E. Geller, does not end once scientists publish.  The true battle is implementing that research to affect global change.  Dr. Stacie E. Geller, Director of the Center for Research on Women and Gender at the University of Illinois at Chicago College of Medicine, puts research into practice by providing safe, affordable medication to pregnant women in developing countries.  Dr. Geller spoke last week at a forum held at Northwestern University’s Feinberg School of Medicine and presented her research on Postpartum Hemorrhaging (PPH) and its dangers to women in developing countries.
In 2008, there were an estimated 358,000 maternal deaths occurring during childbirth, 99% of these deaths occurring in developing countries. Such global disparities are reflected in the limited access to skilled birth attendants, restricted access to medications, rudimentary delivery facilities, and complications surrounding reliable transportation and communication in developing countries.  Postpartum Hemorrhaging (PPH) is the leading cause of maternal mortality worldwide, accounting for 30-50% of all maternal deaths in Africa and Asia alone.  While the drug Oxytocin is used to prevent PPH in developed countries, developing countries do not have the resources to preserve and administer this drug.  Dr. Geller began studying the drug Misoprostol as an alternative to Oxytocin to be used in developing countries due to its low-maintenance storage and cost-effectiveness.
Dr. Geller, along with a team of researchers traveled to communities in India and Ghana to study Misoprostol for prevention of PPH in home-birth settings.  Their research proved that Misoprostol provides a safe and efficacious alternative to Oxytocin in these communities, but Dr. Geller didn’t stop there.  She worked with the Indian Ministry of Health to approve the use of Misoprostol for PPH prevention by Auxillary Nurse Midwives (ANMs). In Ghana, Dr. Geller engaged with health stakeholders at all levels, conducted community sensitization and trainings, monitored the safe use of Misoprostol, and empowered women to take control of their health.  Furthermore Dr. Gellar’s success strengthened the networks of health providers, decreased maternal mortality and morbidity (due to PPH), and established a model for all of Ghana and other developing countries.  Dr. Geller was a primary advocate credited for Misoprostol’s addition to the WHO’s list of essential medications for the prevention of PPH in 2011, an accreditation which has a lasting global impact.
Dr. Geller stresses the importance of political will in enacting policy changes from scientific research.  Government engagement is critical in reducing maternal deaths, and a scientist’s work is not over once research is published.  Advocating for women’s sexual and reproductive rights, their access to equal treatment, and their right to effective medicine should inspire all researchers to utilize their knowledge to facilitate global change.
To read more about Dr. Stacie Geller and her ongoing research, please click here.
 

Scientists discover cause of immature eggs’ death from cancer drug and how to prevent it

MEDIA CONTACT: Marla Paul at (312) 503-8928 or marla-paul@northwestern.edu

CHICAGO — Young women who have cancer treatment often lose their fertility because chemotherapy and radiation can damage or kill their immature ovarian eggs, called oocytes. Now, Northwestern Medicine® scientists have found the molecular pathway that can prevent the death of immature ovarian eggs due to chemotherapy, potentially preserving fertility and endocrine function.

Scientists achieved this in female mice by adding a currently approved chemotherapy drug, imatinib mesylate, to another chemotherapy drug cisplatin.

The results will be presented Monday, June 17, at The Endocrine Society’s 95th Annual Meeting in San Francisco.

“This research advances the efforts to find a medical treatment to protect the fertility and hormone health of girls and young women during cancer treatment, “ said So-Youn Kim, the lead investigator and a postdoctoral fellow in the laboratory of Teresa Woodruff, chief of fertility preservation at Northwestern University Feinberg School of Medicine.

Adding imatinib mesylate to the drug cisplatin blocks the action of a protein that triggers a cascade of events resulting in death of the immature eggs. Kim discovered the protein that triggers the oocyte’s ultimate death is Tap63.

Previous research suggested that imatinib is a fertility-protecting drug against cisplatin, but reports of the drug’s effectiveness have been contradictory, Kim said. Her research confirms its effectiveness in an animal model.

She is currently testing imatinib with other chemotherapy agents to see if it also protects fertility in combination with them.

To demonstrate that imatinib protects oocytes against cisplatin, Kim and colleagues cultured ovaries (containing the immature eggs) from five-day-old mice with imatinib and cisplatin for 96 hours. The ovaries were then placed in a kidney capsule in the host mice to keep the ovaries alive. Two weeks later, the immature eggs were still alive. The imatinib did not block cisplatin-induced DNA damage, but Kim believes the eggs may recover and repair the damage over time.

“Previous reports have shown that chemotherapy and radiation-treated oocytes are able to recover from DNA damage,” Kim said.

The research was funded by the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health, grant U54 HD076188.

NORTHWESTERN NEWS: www.northwestern.edu/newscenter/